DEA Sets New Import, Export Restrictions for Mesocarb
The Drug Enforcement Administration is listing mesocarb, a substance with stimulating properties marketed in Russia for treatment of attention deficit hyperactivity disorder that has no approved medical use and no known therapeutic application in the U.S., under Schedule I of…
Sign up for a free preview to unlock the rest of this article
Communications Daily is required reading for senior executives at top telecom corporations, law firms, lobbying organizations, associations and government agencies (including the FCC). Join them today!
the Controlled Substances Act, it said in a notice published Nov. 22. “This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess), or propose to handle mesocarb," DEA said. The listing takes effect Dec. 22.